Masonic Cancer Center

A comprehensive cancer center designated by the National Cancer Institute

Transplant Biology and Therapy

About the Transplant Biology and Therapy Program

AHCMCC2 - Image - 180x272 - Daniel WeisdorfAHCMCC2 - Image - 180x272 - John Wagner Program Leaders:

John Wagner, M.D.
Daniel Weisdorf, M.D.

The Transplant Biology and Therapy Research Program has 41 members representing five departments and three schools within the Academic Health Center at the University of Minnesota.

Members of this program seek to reduce or eliminate factors limiting hematopoietic stem cell transplantation, such as regimen-related toxicities, graft-versus-host disease (GVHD), and delayed reconstitution of immunity. These scientific goals are accomplished through the development of novel treatment strategies from preclinical studies to early clinical testing in the following themes:

  • Hematopoietic reconstitution
  • Immunological reconstitution -GVHD prevention and treatment
  • Immunological reconstitution - Thymus
  • Relapse prevention and treatment
Umbilical Cord Transplantation Program
Program Meeting Schedule 
    Research Program Members
  • AHCMCC2 - Image - 70x80 - Aurora Mukta

    arora005@umn.edu
    612-624-0123

    Mukta Arora, M.D.
    Development of novel strategies for preventing chronic GVHD and identification of risk factors

    AHCMCC - Image - 70x80 - Veronika Bachanova

    bach0173@umn.edu
    612-624-0123

    Veronika Bachanova, M.D., Ph.D.
    Immune-based therapies for lymphoma and other related malignancies

    AHCMCC - Image - 70x80 - Nelli Bejanyan

    nbejanya@umn.edu
    612-624-6982

    Nelli Bejanyan, M.D.
    Development of novel clinical trials for reducing the early complications of allogeneic HCT and limiting myeloid leukemia recurrence.

    AHCMCC - Image - 70x80 - Bruce Blazar

    blaza001@umn.edu
    612-626-1926

    Bruce Blazar, M.D.
    Regulation of the immune response after allogeneic HCT using murine model systems, development of immune-based therapies (e.g., use of Treg cells to modulate engraftment and GVHCO, and development of stem cell-based therapies for tissue repair after chemoradiotherapy.

    AHCMCC - Image - 70x80 - Claudio Brunstein

    bruns072@umn.edu
    612-624-0123

    Claudio Brunstein, M.D., Ph.D.
    The application of unrelated cord blood transplantation in adults; clinical trials evaluating a) complement fragment 3a (C3a) as a method for enhancing the home of UCB HSC to the hematopoietic niche, b) UCB-derived Treg as a strategy to reduce or prevent acute GVHD, and c) CTN trials exporting the use of the double UCB platform in the context of non-myeloablative conditioning

    AHCMCC - Image - 70x80 - Burns_Linda

    burns019@umn.edu
    612-624-8144

    Linda Burns, M.D.
    The use of radioantibodies to treat hematopoietic malignancy and identification of late effects in long term adult HCT survivors

    AHCMCC - Image - 70x80 - Chen_Wei

    chenw@umn.edu
    612-625-7609

    Wei Chen, M.D., Ph.D.
    Development of immune-based therapeutics - dendritic cell vaccines and use of Toll-like receptor agonists to modulate responses to lymphoid and brain tumors.

    AHCMCC - Image - 70x80 - Cooley_Sarah

    cool0023@umn.edu
    612-625-8474

    Sarah Cooley, M.D.
    Development of NK cell-based immunotherapies to treat leukemia and breast cancer

    AHCMCC - Image - 70x80 - Geller_Melissa

    gelle005@umn.edu
    612-626-3111

    Mellisa Geller, M.D., M.S.
    Ovarian cancer and the treatment of uterine sarcomas, identification early in the course of treatment of the alterations in biomarker and gene profiles that will predict response to chemotherapy

    AHCMCC - Image - 70x80 - Gupta_Pankaj

    gupta013@umn.edu
    612-467-4135

    Pankaj Gupta, M.D.
    The role of proteoglycans in hematopoiesis and interactions between normal and leukemic stem cells with the microenvironment

    AHCMCC - Image - 70x80 - Hippen_Keli

    hippe002@umn.edu
    612-625-1430

    Keli Hippen, Ph.D.
    Translational development of nTreg and iTreg from adult peripheral blood and UCB, T progenitors from UCB and large scael manufacture of UCB CD19 T-CAR as a strategy for eradicating residual CD19+ malignancies

    AHCMCC - Image - 70x80 - Susanta Hui

    huixx019@umn.edu
    612-626-4484

    Susanta Hui, Ph.D.
    Development of a radioactive calcium (41Ca) tracer for early detection of bone remodeling; development of quantitative computed tomorgraphy; quality of life of cancer survivors; anatomical image-guided conformal targeted radiation and confirmal avoidance of critical organs and real-time intra-fraction body motion tracking and  impact on targeted radiation therapy

    AHCMCC - Image - 70x80 - Jacobson_Pamala

    jacob117@umn.edu
    612-624-6118

    Pamala Jacobson, PharmD.
    Pharmacokinetics/pharacodynamics of chemotherapeutic and immunosuppressive agents for prevention of therapy-related complications

    AHCMCC2 - Image - 70x80 - Johnson L'Aurelle

    joh02745@umn.edu
    612-624-5430

    L'Aurelle Johnson, Ph.D.
    Effects of chemotherapy in cancer patients and how responses differ depending on genetics and other factors

    AHCMCC - Image - 70x80 - Kaufman_Dan

    kaufm020@umn.edu
    612-624-0922

    Dan Kaufman, M.D., Ph.D.
    Lympho-hematopoietic differentiation of embryonic stem cells and potential use in tissue repair and reconstitution

    AHCMCC - Image - 70x80 - Kikyo_Nobuaki

    kikyo001@umn.edu
    612-624-0498

    Nobuaki Kikyo, M.D., Ph.D.
    Mechanisms of nuclear reprogramming and how differentiated somatic nuclei are de-differentiated in egg cytoplasm and re-differentiated during subsequent embryogenesis

    AHCMCC2 - Image - 70x80 - Kyba Michael

    kyba@umn.edu
    612-626-5869

    Michael Kyba, Ph.D.
    The differentiation of embryonic and induced pluirpotential stem cells into muscle and hematopoietic stem cells

    AHCMCC - Image - 70x80 - Le_Chap

    chap@umn.edu
    612-624-9963

    Chap Le, Ph.D.
    Data-driven and include epidemiological methods, cross-over designs, survival analysis, ordered alternatives, ROC curves, and methods for the analysis of in vitro experiments—especially chemo-combination therapy

    AHCMCC2 - Image - 70x80 - Lund Troy

    lundx072@umn.edu
    612-625-4185

    Troy Lund, M.D., Ph.D.
    Understanding the pathophysiological processes underlying metabolic storages diseases (ALD, MLD, MPSI, ETC) and improving the outcomes for metabolic storage disease hematopoietic cell transplantation using the zebrafish model; hematopoietic cell engraftment process during bone marrow transplantation and improving the efficiency and time to engraftment

    AHCMCC - Image - 70x80 - MacMillan_Margaret

    macmi002@umn.edu
    612-626-2778

    Margaret MacMillan, M.D.
    Prevention and treatment of acute GVHD; clincial trials using iTreg for prevention of acute GVHD in recipients of HLA-matched peripheral blood stem cells

    AHCMCC - Image - 70x80 - McClune_Brian

    bmcclune@umn.edu
    612-624-0123

    Brian McClune, D.O.
    Clinical trials in hematologic malignancy using stem cell transplantation

    AHCMCC2 - Image - 70x80 - McCullough Jeffrey

    mccul001@umn.edu
    612-626-3272

    Jeffrey McCullough, M.D.
    Transfusion medicine as it relates to cancer and HCT patients (e.g. leukocyte infusions in sepsis, platelet alloimmunization); development of novel therapies

    AHCMCC - Image - 70x80 - McGlave_Phillip

    mcgla001@umn.edu
    612-624-0123

    Phillip McGlave, M.D.
    Treatment of malignant and nonmalignant hematologic disorders including aplastic anemia, leukemia, lymphoma, multiple myeloma, myelodysplasia, and blood and marrow transplantation; experimental therapy for malignant and non-malignant hematologic disorders including stem cell transplantation, immunotherapy, and gene transfer

    AHCMCC - Image - 70x80 - McKenna_David

    mcken020@umn.edu
    612-624-5736

    David McKenna, Jr., M.D.
    Development of novel cellular therapies

    AHCMCC - Image - 70x80 - Jeffrey Miller

    mille011@umn.edu
    612-625-7409

    Jeffrey Miller, M.D.
    Development of immune-based therapeutics

    MEDPEDS2 - Image - 70x80 - Wes Miller

    mill4991@umn.edu
    612-626-2778

    Weston Miller, M.D.
    Development of novel clinical HCT trials in patients with metabolic disease; understanding the impact of high resolution HLA matching of UCB

    MEDPEDS2 - Image - 70x80 - Paul Orchard

    orcha001@umn.edu
    612-626-2313

    Paul Orchard, M.D.
    Development of immune-based therapeutics

    MEDPEDS2 - Image - 70x80 - Mark Osborn

    osbor026@umn.edu
    612-624-0474

    Mark Osborn, Ph.D.
    Biology of homologous recombination as a strategy for gene transfer into HSC of patients with various genetic diseases, including Fanconi anemia

    AHCMCC - Image - 70x80 - Panoskatsis-Mortari

    panos001@umn.edu
    612-626-2950

    Angelea Panoskaltsis-Mortari
    The pathophysiology of acute lung injury in the setting of allogeneic HCT and GVHD and leads studies in pulmonary regenerative medicine

    AHCMCC - Image - 70x80 - Slungaard_Arne

    slung001@umn.edu
    612-624-0123

    Arne Slungaard, M.D.
    Inflammatory mediators of coagulation and vascular integrity with direct relevance to tumor vascularity and thrombosis in patients with cancer

    AHCMCC - Image - 70x80 - Smith_Angela

    smith719@umn.edu
    612-626-2778

    Angela Smith, M.D., M.S.
    Early and late effects of HCT, with a focus on venoocclusive disease of the liver and infertility

    MEDPEDS2 - Image - 70x80 - Heather Stefanski

    stef0030@umn.edu
    612-626-2961

    Heather Stefanski, M.D., Ph.D.
    Thymic epithelial cell protection and expansion of T progenitors (Tprog) extrapolated from the murine model

    AHCMCC - Image - 70x80 - Tolar_Jakub

    tolar003@umn.edu
    612-625-2912

    Jakub Tolar, M.D., Ph.D.
    Development of non-hematopoietic stem cells for use in tissue repair particularly precancerous genetic diseases like epidermolysis bullosa, dykeratosis congentia and Fanconi anemia.

    AHCMCC2 - Image - 70x80 - Ustun Celalettin

    custun@umn.edu
    612-624-0123

    Celalettin Ustun, M.D.
    Clinical trials for acute myeloid leukemia and related myeloid malignancies

    AHCMCC2 - Image - 70x80 - Vercellotti Gregory

    verce001@umn.edu
    612-624-0123

    Gregory Vercellotti, M.D.
    Inflammation, oxidative stress and endothelial integrity

    AHCMCC - Image - 70x80 - Verneris_Michael

    verneris@umn.edu
    612-626-2961

    Michael Verneris, M.D.
    NK cell development and therapies; biology of immune reconstitution after allogenic BMT; clinical studies using total marrow irradiation

    AHCMCC - Image - 70x80 - John Wagner

    wagne002@umn.edu
    612-626-2961

    John Wagner, M.D.
    Development of UCB as a source of hematopoietic and non-hematopoietic stem cells for treatment of malignancy; pathophysiology of Fanconi anemia and Epidermolysis bullosa predisposition to malignancy

    AHCMCC - Image - 70x80 - Warlick_Erika

    ewarlick@umn.edu
    612-624-0123

    Erica Warlick, M.D.
    The development of new strategies utilizing hematopoietic stem cell transplantation, traditional chemotherapeutics, as well as novel biologic modifiers to treat this diverse group of diseases

    AHCMCC - Image - 70x80 - Weigel_Brenda

    weige007@umn.edu
    612-626-5501

    Brenda Weigel, M.D.
    Testing new pharmacological and cellular therapeutic agents in preclinical mouse models and phase 1 testing in children

    AHCMCC - Image - 70x80 - Daniel Weisdorf

    weisd001@umn.edu
    612-624-3101

    Daniel Weisdorf, M.D.
    Application of transplant therapy for acute leukemia as well as prevention and treatment of acute and chronic GVHD and late effects of HCT

  • ©2014 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on May 29, 2014